benzamide thiocarbonyl compound imidazolidinone enzalutamide http://purl.bioontology.org/ontology/RXNORM/1307298 http://purl.bioontology.org/ontology/SNOMEDCT/703125003 http://purl.obolibrary.org/obo/CHEBI_68534 http://purl.obolibrary.org/obo/NCIT_C71744 https://en.wikipedia.org/wiki/Enzalutamide https://www.wikidata.org/wiki/Q1996756 A benzamide obtained by formal condensation of the carboxy group of 4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl}-2-fluorobenzoic acid with methylamine. Used for the treatment of of metastatic castration-resistant prostate cancer. An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance. L02BB04 (trifluoromethyl)benzene monofluorobenzene